Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
In Vivo (Athens, Greece)|November 20, 2012
No compensation in VEGF expression follows antisense suppression of BCL-2 activityMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|February 21, 2013
No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotidesMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|April 1, 2003
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxolMarvin Rubenstein, Leonid Slobodskoy, Yelena Mirochnik, et al.
International Journal of Biometeorology|October 28, 2016
ENSO and PDO-related climate variability impacts on Midwestern United States crop yieldsChasity Henson, Patrick Market, Anthony Lupo, et al.
Medical Oncology (Northwood, London, England)|April 28, 2010
Bax expression remains unchanged following antisense treatment directed against BCL-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2013
Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|November 8, 2015
Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor ProliferationMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Hypotheses|November 25, 2010
Does the prostate retain an endogenous antiviral defense system suggesting a past viral etiology for cancer?Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Pageof 4